12:00 AM
May 06, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Actavis, Shire sales and marketing update

Shire granted Actavis a license to market a generic version of Shire's ADHD drug Intuniv guanfacine in the U.S. beginning on Dec. 1, 2014. Actavis will have exclusive rights to market generic Intuniv for 180 days, during which Shire will receive 25% royalties of gross profits. Additionally, Shire granted Watson Pharmaceuticals Inc.,...

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >